McNeil settles sweet suit
This article was originally published in The Tan Sheet
Executive Summary
A trademark infringement lawsuit filed by the Sugar Association against McNeil Nutritionals in December 2004 has been settled, the Fort Washington, Pa.-based company announces Nov. 17. The parties are not disclosing details of the settlement of the suit in the U.S. District Court for the Central District of California. McNeil was sued for stating its Splenda artificial sweetener is "made from sugar so it tastes like sugar" (1"The Tan Sheet" Feb. 7, 2005, In Brief). A separate lawsuit filed by Equal and NutraSweet marketer Merisant, also claiming the Splenda tagline was false and misleading, was settled with McNeil in May 2007 (2"The Tan Sheet" May 21, 2007, In Brief)
You may also be interested in...
Stevia Products Roll Out As GRAS, But Must Win Over Consumer Sweet Tooth
Stevia-based sweeteners are enjoying a coming out party with FDA giving the go-ahead to Cargill's Truvia and Merisant's PureVia
Splenda ads not so sweet
McNeil Nutritionals is being sued by Equal- and Nutrasweet-marketer Merisant and the Sugar Association in separate suits filed in Pennsylvania and California district courts, respectively. Both suits allege Splenda ads that state "Made from sugar so it tastes like sugar" are false and misleading because the sweetener is made from sucralose, a synthetic chemical ingredient, the Merisant complaint states. Both Merisant and the Sugar Association are asking McNeil to be enjoined from marketing Splenda as an all-natural substance and request monetary compensation for damages and attorneys fees. McNeil also should run a corrective ad campaign "of comparable size and scope...clarifying that Splenda is not sugar or natural, but is an artificial sweetener," Merisant adds...
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.